Thinly traded nano cap Lipocine (NASDAQ:LPCN) is up 125% premarket on robust volume following its announcement of encouraging data from an open-label single-arm study evaluating NASH candidate LPCN 1144 in 36 hypogonadal males with at least 10% baseline liver fat.
Interim data on seven patients with average baseline liver fat of 21% showed an absolute reduction from baseline of 7.6% and a 38% relative reduction. The responder rate was 86% (n=6/7) (defined as at least a 4.1% absolute reduction in liver fat) and 71% (n=5/7) with a 29% absolute reduction criterion.
No new safety signals were observed.
16-week data should be available later this quarter.
LPCN 1144 is an oral prodrug of what the company says is “bioidentical” testosterone.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.